|Daily Range||$34.10 - $34.56|
|52-Week Range||$32.08 - $38.15|
|Dividend (Yield)||$0.00 (2.6%)|
|Average Daily Volume||1,512,145|
|Current FY EPS||$1.88|
These three biotechs have promising drugs in their pipelines that address billion dollar drug markets.
Phase 1 trial results for Prothena Corporation's PRX-002 could indicate that this drug may help treat Parkinson's disease someday.
Takeda Pharmaceutical has licensed ImmunoGen's antibody-drug conjugate technology.
With the regulatory pathway cleared, the biosimilars market is poised to turn into a gold mine, growing up to 6,250% in 10 years. Here's where to stake your claim.
Motley Fool contributor Todd Campbell offers up two dividend-paying healthcare stocks to avoid and one that could be a good buy for long-term income investors.
Results for Prothena's early-stage Parkinson's disease drug, PRX-002, have sent shares surging.
Despite reporting a net loss, Inovio's research pipeline opportunity boosts shares.
Exelixis shares soared in February as shareholders await two key catalysts.
Xoma Corporation could release late stage trial data that could significantly move the stock.
Pharmacyclics soars higher following reports that the company may put itself up for sale.